Bigelow Tea on YouTube Subscribe Follow Me on Pinterest Follow Us on Instagram

Bigelow Tea Recognizes November As National Diabetes Month

The number is huge: 25.8 million people in the United States have diabetes. And, believe it or not, 7 million of them haven’t been diagnosed yet. When we add to that the 79 million people with pre-diabetes it’s easy to see why November has been designated National Diabetes Month and National Diabetic Eye Disease Month. With these statistics in mind, it’s clear that we all should support efforts to heighten the awareness of these diseases.

Diabetes is group of metabolic diseases (Type 1, Type 2, Gestational, etc.) that cause a person to have high blood sugar, either because the body does not produce enough insulin or because its cells don’t respond to the insulin that is produced by the body. Although all types are treatable, the management of each type is different. Some types can be managed through diet and exercise, but others need to be treated with medication, possibly via injections. When diabetes isn’t managed correctly, it can trigger complications such as Diabetic Eye Disease, a leading cause of blindness in American adults.

On October 29, 2010 the President of the United States made a Presidential Proclamation stating that U.S. citizens should raise awareness to help prevent, treat, and manage this disease.

Bigelow Tea is pleased to help raise awareness of Diabetes this month. We’ve been told time and again that our teas are so flavorful that they can be sipped when the craving for a sugary dessert strikes! Because they contain no sugar, our teas—greenherbalblack and decaf—are a delicious option for any time of day!

We all know that when we have a problem, big or small, it helps to talk about it. Diabetes is no minor issue … so let’s start talking about it, and let’s start figuring out how we can help our friends and family members who have diabetes. November is National Diabetes Month; it’s a perfect time to start.

Image by Woodleywonderworks via

Tags: , , , ,

Comments are closed.